Drug Profile

AGMB 101

Alternative Names: AGMB-101; ARGX-114

Latest Information Update: 29 Oct 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator AgomAb Therapeutics
Class Anti-inflammatories; Antifibrotics; Monoclonal antibodies
Mechanism of Action Proto-oncogene protein c-met stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Autoimmune disorders; Fibrosis; Inflammation; Liver failure; Soft tissue injuries

Most Recent Events

25 Oct 2024 Agomab Therapeutics plans to develop AGMB 101 for Liver cirrhosis
04 Nov 2022 The pharmacodynamics data from preclinical studies in acute liver failure presented at the American Association for the Study of Liver Diseases (AASLD-2022)
03 Nov 2022 Preclinical trials in Liver failure in Belgium (Parenteral) before November 2022

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com